The Post-Aromatase Battlefield: Breaking Down Eli Lilly's Inluriyo Strategy, Companion Diagnostic Moats, and the Oral SERD Market Shift
Dr. Dereck Mush, MD, MBA
Eli Lilly and Company
Global drugmaker behind Inluriyo, the oral SERD approved with Verzenio for ESR1 mutated breast cancer.
What they do
Eli Lilly is a global pharmaceutical company with a deep oncology franchise. In September 2026 the FDA approved Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for ER positive, HER2 negative, ESR1 mutated advanced breast cancer after endocrine therapy, based on the phase 3 EMBER-3 trial.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Targeted oncology
- Product type
- Platform software
- Stage
- Public
- Headquarters
- Indianapolis, United States
- Region
- North America
- Founded
- 1876
- Total funding
- Undisclosed
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
The Non-Covalent Oncology Paradigm: Jaypirca's Frontline Infiltration and the BTK Landscape
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
The Radiopharmaceutical Infrastructure Playbook: Why Telix's FDA Approval for Pixclara Redefines Neuro-Oncology Diagnostics and Theranostics
Dr. Dereck Mush, MD, MBA